Lucinactant

Jump to navigation Jump to search
Lucinactant
Combination of
[[{{{component5}}}]]? Class
Clinical data
Trade namesSurfaxin
ATC code
Identifiers
CAS Number
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).

WikiDoc Resources for Lucinactant

Articles

Most recent articles on Lucinactant

Most cited articles on Lucinactant

Review articles on Lucinactant

Articles on Lucinactant in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Lucinactant

Images of Lucinactant

Photos of Lucinactant

Podcasts & MP3s on Lucinactant

Videos on Lucinactant

Evidence Based Medicine

Cochrane Collaboration on Lucinactant

Bandolier on Lucinactant

TRIP on Lucinactant

Clinical Trials

Ongoing Trials on Lucinactant at Clinical Trials.gov

Trial results on Lucinactant

Clinical Trials on Lucinactant at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Lucinactant

NICE Guidance on Lucinactant

NHS PRODIGY Guidance

FDA on Lucinactant

CDC on Lucinactant

Books

Books on Lucinactant

News

Lucinactant in the news

Be alerted to news on Lucinactant

News trends on Lucinactant

Commentary

Blogs on Lucinactant

Definitions

Definitions of Lucinactant

Patient Resources / Community

Patient resources on Lucinactant

Discussion groups on Lucinactant

Patient Handouts on Lucinactant

Directions to Hospitals Treating Lucinactant

Risk calculators and risk factors for Lucinactant

Healthcare Provider Resources

Symptoms of Lucinactant

Causes & Risk Factors for Lucinactant

Diagnostic studies for Lucinactant

Treatment of Lucinactant

Continuing Medical Education (CME)

CME Programs on Lucinactant

International

Lucinactant en Espanol

Lucinactant en Francais

Business

Lucinactant in the Marketplace

Patents on Lucinactant

Experimental / Informatics

List of terms related to Lucinactant

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]

Overview

Lucinactant (trade name Surfaxin) is a liquid medication used to treat infant respiratory distress syndrome.[1] It was approved for use in the United States by the U.S. Food and Drug Administration (FDA) on March 6, 2012.[2]

Medical uses

Lucinactant is indicated to improve lung function and reduce duration and risk of mechanical ventilation in children. It can be used up to two years of age and is specified for children who are diagnosed with acute respiratory failure following exposure to a pathogen such as RSV or influenza, including H1N1.[3][4][5] Lucinactant is also used to treat meconium aspiration syndrome.[5][6]

Physical and chemical properties

Lucinactant contains the peptide sinapultide (KL4 acetate), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (as the sodium salt), and palmitic acid.

History

The scientific groundwork for lucinactant was laid in the laboratory of Charles Cochrane at The Scripps Research Institute in the 1990s.[7] The drug was then developed by Discovery Laboratories of Warrington, PA. The path through the approval process was unusually long, reflecting in part challenges in the manufacturing process that needed to be addressed before approval was granted.[8]

Legal status

Lucinactant is listed as an Orphan Drug Product by the US Food and Drug Administration for several conditions:[9][10]

  • 07-30-1996 Treatment of meconium aspiration syndrome in newborn infants
  • 07-17-1995 Treatment of acute respiratory distress syndrome in adults.
  • 05-23-2006 Prevention of bronchopulmonary dysplasia in premature infants
  • 10-21-2005 Treatment of bronchopulmonary dysplasia in premature infants.
  • 10-18-1995 Treatment of respiratory distress syndrome in premature infants.

Clinical trials in Latin America were criticized for protocol based in potentially unethical principles.[11] A placebo was used and considered ethical by design since infants born in Latin America usually do not have access to life saving treatment. The intent of Discovery Labs was always to market Surfaxin in the United States, implying burdens on the Latin American children that outweighed the benefits.

References

  1. [1][dead link]
  2. "FDA approves Surfaxin to prevent breathing disorder in premature infants". Fda.gov. 2012-03-06. Retrieved 2012-10-20.
  3. http://money.cnn.com/news/newsfeeds/articles/globenewswire/182115.htm. Missing or empty |title= (help)[dead link]
  4. PMID 10508806 (PMID 10508806)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  5. 5.0 5.1 PMID 15833063 (PMID 15833063)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  6. PMID 12042546 (PMID 12042546)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  7. "Scripps Research Discoveries Lead to Newly Approved Drug for Infant Respiratory Distress Syndrome". Scripps.edu. 2012-03-06. Retrieved 2012-10-20.
  8. "Pharmaceutical News - Discovery Labs Turns Focus To Surfaxin Market Strategy - October 20, 2012". Pharmacy Choice. Retrieved 2012-10-20.
  9. "List Of Orphan Products Designations And Approvals". Google2.fda.gov. Retrieved 2012-10-20.
  10. "Page expired". Nelm.nhs.uk. Retrieved 2012-10-20.
  11. Charatan, Fred (10 March 2001). "Surfactant trial in Latin American infants criticised". BMJ. 7286. 322: 575. doi:10.1136/bmj.322.7286.575/b. PMC 1119782. PMID 11238147.